![]() He and his co-founder identified mitochondrial base editing as a focus that could enable innovative drug discovery to significantly impact patients living with mitochondrial diseases. Kang founded March Therapeutics at a time when many companies were focused on CRISPR gene editing. She points out that an individual contributor may be a critical leader in the team, while a manager is not always a leader. Julie’s experience managing teams and contributing to build in a variety of ways has solidified her belief that boss, manager, and leader are used interchangeably, but they are so distinct. ![]() Julie O'Shaughnessy, a seasoned operator, startup advisor, and Head of Digital at Resilience, says that new founders can’t let their focus on product lead to neglecting the other key ingredients for success: people and culture. Ross finds that even small, supportive behavior like giving his team the time and space to talk about whatever is important to them, can significantly impact their motivation level, regardless of how intrinsically talented they may be. Throughout his career, 82VS Venture Partner Ross Leimberg has adopted the mantra that great leaders lead by example. And the steadfast, mighty network she has built over the years proves her point. In her experience, the best things about being a founder is that you can choose who you work with. She is driven to apply her business talent to bring novel technologies to the market. Lynne Frick, CEO of Cell X Technologies, is a serial entrepreneur with a knack for choosing the right tech and bringing it to maturity at the right time. This is especially critical for first time founders who have to learn how to navigate risk - the advisors and team can be instrumental to better decision-making. In this panel, Tarek shares that success in biotech is rooted in relationships. Some stand-out snippets from each of the speakers:Īt Massachusetts Institute of Technology, Director of Strategic Alliances and Partnerships Tarek Fadel sits at the intersection of cutting edge discovery in academic labs and fast-paced translation in industry. ![]() You can listen to the audio recording here. ![]() Recently, we hosted a panel event on effective leadership for biotech success. Moving towards a world where data streams are better standardized and built with science in mind will help everyone across the R&D ecosystem and we are thrilled to be a part of the journey! We at Kaleidoscope take data transparency and innovation very seriously so we are excited to see these efforts being taken across the federal government to improve on these practices. We learned about the AR tools under development for improved training of healthcare professionals, participated in breakout sessions with thoughtful leaders including Krishna Juluru, MD and Susan Kirsh MD MPH, and met up with changemakers in the healthcare and life sciences scene Freddy Nguyen, MD, PhD and Azade Hosseini, PhD! The Federal Health Innovation Day at NODE.Health's Digital Medicine Conference ( ) in NYC was similarly informative and a great way to get insights from a number of healthcare policy-makers all in one place. Creating a consistent vocabulary for the data fields is critical!” This is one of the core principles upon which Kaleidoscope is based: moving away from the diary-esque, messy world of current ELNs to the best practices of data standardization. As Ali Russo mentioned during talks on CDRH’s data modernization efforts, “data needs to be integrated and in one place to be strategically useful. With the goal of working in concert with tech partners large and small, FDA is aiming to adapt to the ever-evolving tech landscape in order to better safeguard the health of Americans everywhere. They’ve recognized that over the years they’ve developed tools across the organization in silo-ed, disjointed ways and this lack of transparency has led to inefficiencies and redundancies. The FDA Digital Transformation Symposium ( ) highlighted the various #MAPs (Modernization Action Plans) FDA has compiled to become more proactive in their enterprise-wide IT strategy. Kaleidoscope goes to Washington! Last week, Kaleidoscope’s science leads Sunny and Mandana had a great time at two government events highlighting the actions various agencies are taking to modernize their technology stack and support digital health innovation. The path to a marketed drug ultimately requires regulatory approval by the FDA, but how can digital transformation within government agencies and biotechs de-risk and accelerate this exhaustive journey from #benchtobedside?
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |